Residency · Residency · Child Adolescent Psychiatry
Pediatric Major Depressive Disorder: Diagnosis and Treatment
Overview
Major depressive disorder affects approximately 2% of prepubertal children and 4-8% of adolescents, with a lifetime prevalence of 11-14% by age 18. Depression in youth is commonly underdiagnosed because irritability is often more prominent than sadness, and symptoms may be dismissed as "normal" adolescence. The Treatment for Adolescents with Depression Study (TADS) established fluoxetine combined with CBT as the optimal initial treatment for moderate-to-severe adolescent depression. Untreated depression in youth is associated with academic failure, substance use, interpersonal difficulties, and suicide.
Developmental Modifications in Presentation
Prepubertal Children
In prepubertal children, irritability is typically the predominant mood disturbance rather than the sadness that characterizes adult depression. Somatic complaints — headaches and stomachaches — are common presenting symptoms and may be the chief complaint that brings the family to medical attention. Depression may present as behavioral problems including aggression, tantrums, and school refusal. Anhedonia manifests as loss of interest in play, friends, or previously enjoyed activities. Psychomotor agitation is more common than retardation. Guilt may be expressed as excessive self-blame or a pervasive feeling of being "bad." Suicidal ideation can be present even in young children, though completed suicide is rare before age 10. Separation anxiety may co-occur or overlap with depressive symptoms.
Adolescents
Adolescent depression more closely resembles the adult presentation but retains notable differences. Irritability remains prominent and is recognized as an alternative to depressed mood in the DSM-5 criteria for youth. Hypersomnia and increased appetite with weight gain are more common than in adults, reflecting atypical features. Academic decline is frequently an early and prominent sign. Social withdrawal from peers and family, substance use as self-medication, and increased risk-taking behavior may all be present. Suicidal ideation is more common and carries greater lethality in adolescents compared to children.
DSM-5 Criteria Considerations
The DSM-5 applies the same criteria for MDD in children and adolescents as in adults, with one key modification: irritable mood can substitute for depressed mood. The duration requirement remains at least 2 weeks. Failure to make expected weight gains (rather than weight loss) is included as a criterion. Five of nine symptoms are required, with at least one being depressed or irritable mood or anhedonia.
Assessment
Clinical Interview
The clinical interview should involve the child or adolescent both alone and with caregivers. Adolescents may disclose symptoms they hide from parents, including suicidal ideation, substance use, and self-harm. Parents often provide better information about the timeline of symptoms and functional impairment. All symptom domains should be assessed: mood, anhedonia, sleep, appetite, energy, concentration, psychomotor changes, guilt, and suicidal ideation. Screening for comorbid conditions is essential, as anxiety co-occurs in approximately 70% of cases, and ADHD, substance use, and eating disorders are also common.
Rating Scales
Several validated instruments aid assessment. The PHQ-A (Patient Health Questionnaire for Adolescents) is a brief, validated self-report screener. The CDI-2 (Children's Depression Inventory) is a widely used self-report measure for ages 7-17. The CDRS-R (Children's Depression Rating Scale, Revised) is a clinician-rated instrument most commonly used in clinical trials. The Columbia Suicide Severity Rating Scale (C-SSRS) is an essential suicide risk assessment tool that should be incorporated into every evaluation.
Differential Diagnosis
The differential diagnosis includes adjustment disorder with depressed mood (time-limited and clearly linked to a stressor), DMDD (chronic severe irritability without episodic mood changes), bipolar depression (requiring screening for any history of manic or hypomanic episodes), substance-induced mood disorder, medical conditions (hypothyroidism, anemia, mononucleosis, autoimmune disorders), medication side effects (corticosteroids, isotretinoin, oral contraceptives), normal grief versus complicated bereavement, and ADHD (which overlaps with depression in concentration difficulties, irritability, and academic decline).
The TADS Study (Treatment for Adolescents with Depression Study)
Design
The TADS study was an NIMH-funded multisite RCT enrolling 439 adolescents ages 12-17 with moderate-to-severe MDD. Participants were randomized to one of four treatment arms over 12 weeks: fluoxetine alone (10-40 mg/day), CBT alone, fluoxetine plus CBT (combination), or placebo.
Key Findings (12 weeks)
Combination treatment achieved a 71% response rate, significantly superior to all other groups. Fluoxetine alone achieved a 61% response rate, superior to placebo. CBT alone achieved only a 43% response rate, which was not superior to placebo at the 12-week mark — a controversial finding. Placebo achieved a 35% response rate.
| Treatment Arm | 12-Week Response Rate | Superiority to Placebo | Notes |
|---|---|---|---|
| Fluoxetine + CBT (combination) | 71% | Yes | Best outcomes; lowest suicidal events |
| Fluoxetine alone | 61% | Yes | Reasonable when CBT unavailable |
| CBT alone | 43% | No (at 12 weeks) | Catches up by 36 weeks |
| Placebo | 35% | — | High placebo response; mild depression may respond to monitoring |
Longer-Term Follow-Up (36 weeks)
By 36 weeks, CBT alone had "caught up," with response rates converging across all active treatment arms. Combination treatment showed the fastest and most sustained improvement. Notably, combination treatment was associated with the lowest rates of suicidal events across all groups.
Clinical Implications
For moderate-to-severe adolescent depression, combination treatment (fluoxetine plus CBT) should be first-line. For mild depression, CBT alone or active monitoring may be appropriate given the high placebo response rate. Fluoxetine monotherapy is reasonable when CBT is not available. CBT takes longer to show its full effects compared to medication, and families should be counseled about this timeline.
Pharmacotherapy
Fluoxetine as First-Line
Fluoxetine is the only SSRI with FDA approval for pediatric depression (ages 8 and older). Treatment typically starts at 10 mg/day, increasing to 20 mg/day after 1-2 weeks, with a maximum dose of 60 mg/day (though most patients respond to 20-40 mg). Its long half-life, including the active metabolite norfluoxetine, is advantageous for adherence but requires awareness of extended washout periods. Multiple RCTs demonstrate efficacy with a number needed to treat of approximately 4-5.
Escitalopram
Escitalopram is FDA-approved for adolescent depression in patients ages 12 and older. Starting at 5 mg/day with a target of 10-20 mg/day, it is generally well tolerated and serves as a second-line option after fluoxetine based on the strength of its evidence base.
Other SSRIs
Sertraline and citalopram have some positive trial data but are not FDA-approved for pediatric depression. Paroxetine is not recommended in youth due to negative trials, a higher side effect burden, and problematic withdrawal symptoms. Fluvoxamine has not been studied for pediatric depression (it is approved for OCD).
SNRIs
Duloxetine and venlafaxine have mixed evidence in adolescent depression and are generally reserved for treatment-resistant cases. They carry higher risks of blood pressure elevation and discontinuation syndrome. Venlafaxine showed a concerning signal for suicidality in pediatric trials.
Monitoring During SSRI Treatment
Visits should be scheduled weekly for the first 4 weeks, biweekly for the next 4 weeks, then monthly thereafter. Monitoring should include assessment for activation syndrome (agitation, insomnia, impulsivity), screening for emergent suicidal ideation at every visit (see the Black Box Warning discussion), and assessment for serotonin syndrome symptoms. An adequate trial requires a minimum of 4-8 weeks at a therapeutic dose before concluding inefficacy. If the first SSRI fails, switching to another SSRI should be attempted before moving to an SNRI or augmentation strategy.
Psychotherapy
Cognitive Behavioral Therapy (CBT)
CBT is the most extensively studied psychotherapy for adolescent depression. Core components include behavioral activation, cognitive restructuring, problem-solving skills, and relapse prevention. Adaptations for youth involve concrete examples, worksheets, parent involvement, and shorter sessions for younger children. A typical course is 12-16 sessions. CBT is effective as monotherapy for mild-to-moderate depression and produces the best outcomes when combined with fluoxetine.
Interpersonal Therapy for Adolescents (IPT-A)
IPT-A focuses on interpersonal relationships as the context for depression, addressing role transitions, interpersonal disputes, grief, and interpersonal deficits. It is manualized for adolescents across 12-16 sessions and has a strong evidence base with efficacy comparable to CBT. It may be particularly useful when depression is clearly linked to relational stressors.
Behavioral Activation
Behavioral activation focuses on increasing engagement in rewarding activities and is particularly useful when anhedonia and withdrawal are the predominant symptoms. It can be implemented as a standalone treatment or as a component of CBT, employing activity scheduling, mood monitoring, and graded task assignment.
Treatment-Resistant Depression in Youth
Treatment-resistant depression is defined as failure to respond to two adequate SSRI trials plus psychotherapy. Evaluation should address comorbid conditions, substance use, ongoing stressors, and medication adherence. The TORDIA study demonstrated that switching to a different SSRI plus adding CBT was superior to switching SSRI alone. Augmentation strategies include atypical antipsychotics (with limited pediatric evidence), lithium augmentation (extrapolated from adult evidence), and bupropion. Referral for psychiatric consultation is appropriate if not already involved.
<image>A treatment algorithm for pediatric major depressive disorder. Start with severity assessment: mild (CBT or active monitoring), moderate-to-severe (combination fluoxetine + CBT as first-line). If inadequate response after 8 weeks: reassess diagnosis, check adherence, increase dose. If second SSRI fails: consider TORDIA-guided approach (switch SSRI + add CBT). Third-line: SNRI, augmentation strategies, or specialty referral. Include monitoring schedule at each step.</image>
<image>A bar graph showing the TADS study results at 12 weeks and 36 weeks. Four bars at 12 weeks showing response rates: combination (71%), fluoxetine (61%), CBT (43%), placebo (35%). Show convergence of response rates at 36 weeks. Include annotation about suicidal events across groups and the key clinical takeaway that combination treatment is optimal.</image>
<image>A developmental comparison infographic showing how depression presents differently in prepubertal children vs. adolescents vs. adults. Three columns with age-appropriate symptom manifestations for mood (irritability vs. sadness), anhedonia (loss of play interest vs. social withdrawal), somatic symptoms, sleep changes (insomnia vs. hypersomnia), and suicidality (ideation complexity by age). Include the key message that irritability is a depressive equivalent in youth.</image>
Clinical Pearls
Irritability is the hallmark of pediatric depression and is more common than sadness, especially in younger children. Combination treatment (fluoxetine plus CBT) is first-line for moderate-to-severe adolescent depression per TADS. Fluoxetine is the only SSRI with FDA approval for depression in children ages 8 and older; escitalopram is approved for ages 12 and older. The high placebo response rate (35% in TADS) means that mild depression may respond to active monitoring and supportive care alone. Always interview the adolescent alone, as they may disclose suicidal ideation, substance use, or other concerns they are hiding from parents. CBT works but takes longer than medication — families should be prepared for this timeline. Somatic complaints such as headaches and stomachaches are frequently the presenting complaint of depression in children. Screening for comorbid anxiety, which is present in approximately 70% of depressed youth, is essential and affects treatment planning.
References
- March, J. et al. (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression (TADS). JAMA, 292(7), 807-820.
- Brent, D. et al. (2008). Switching to another SSRI or to venlafaxine with or without CBT for adolescents with SSRI-resistant depression (TORDIA). JAMA, 299(8), 901-913.
- Birmaher, B. et al. (2007). AACAP Practice Parameter for depressive disorders in children and adolescents. JAACAP, 46(11), 1503-1526.
- Weersing, V.R. et al. (2017). Evidence-base update for psychosocial treatments for child and adolescent depression. JCCAP, 46(1), 11-43.
- Cipriani, A. et al. (2016). Comparative efficacy and tolerability of antidepressants for MDD in children and adolescents: network meta-analysis. Lancet, 388(10047), 881-890.
